FY2025 · ended Dec 31, 2025 · Revenue $52.74M, -1.2% YoY · Filed Mar 18, 2026
Protalix BioTherapeutics, Inc. (PLX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $52.7 million and a net loss of $6.6 million. Free cash flow was -$13.6 million. As of Jun 30, 2026 it held $27.4 million in cash and investments and $9.2 million in total debt.
Revenue (TTM)
$80.62M
+30.1% vs year-ago TTM
Net income (TTM)
$18.95M
+201.9% vs year-ago TTM
Operating cash flow (TTM)
$9.92M
+552.1% vs year-ago TTM
Free cash flow (TTM)
$7.67M
+322.6% vs year-ago TTM
EPS (TTM)
$0.23
+210.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
80.57M
+3.3% vs prior year
Net cash
$18.21M
as of Jun 30, 2026
Operating margin
28.9%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PLX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hackensack, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1006281
- Former names
- ORTHODONTIX INC (until Feb 22, 2007); EMBASSY ACQUISITION CORP (until Mar 31, 1998)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M |
| Operating income | -$5.5M | $3.9M | $10.5M | -$13.0M | -$20.5M |
| Net income | -$6.6M | $2.9M | $8.3M | -$14.9M | -$27.6M |
| Diluted EPS | -$0.08 | $0.04 | $0.09 | -$0.31 | -$0.62 |
| Operating cash flow | -$12.0M | $8.7M | -$1.3M | -$25.0M | -$10.3M |
| Free cash flow | -$13.6M | $7.4M | -$2.5M | -$25.6M | -$11.7M |
| Total assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M |
| Total liabilities | $34.1M | $30.2M | $50.9M | $66.4M | $79.7M |
| Stockholders' equity | $48.2M | $43.2M | $33.6M | -$10.6M | -$6.0M |
| Cash and investments | $14.7M | $19.8M | $23.6M | $17.1M | $39.0M |
| Total debt | $8.3M | $5.5M | $6.0M | $5.3M | $5.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 972 Protalix BioTherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.